Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting

Fineline Cube Jul 1, 2026
Company Drug

Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks

Fineline Cube Jul 1, 2026
Company

Alibaba Health Reports Strong 2025 Financial Results with Revenue Hike

Fineline Cube May 20, 2025

China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2025 financial report for the...

Company Drug

CSPC Pharmaceutical’s CPO301 Receives Third FDA Fast Track Designation for NSqNSCLC

Fineline Cube May 20, 2025

China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its EGFR-targeted antibody-drug conjugate (ADC) CPO301...

Company Drug

Merck Sharp & Dohme Initiates Phase III Trial of Ifinatamab Deruxtecan for Esophageal Cancer

Fineline Cube May 20, 2025

US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced the first patient dosing in...

Company Deals

Terumo Corporation Acquires WuXi Biologics’ Germany Plant for EUR 150 Million

Fineline Cube May 19, 2025

Japan-based Terumo Corporation (TYO: 4543) has entered into an agreement with China-based Contract Research, Development...

Company

Grand Pharma’s Chengdu RDC Megafactory Secures Class A Radiation Safety License

Fineline Cube May 19, 2025

Grand Pharmaceutical Group Limited (HKG: 0512) has obtained a Class A Radiation Safety License from...

Company Drug

Shanghai Henlius Biotech Doses First Patient in Phase I/III Study of HLX13 for Hepatocellular Carcinoma

Fineline Cube May 19, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the completion of first patient dosing in a...

Company Medical Device

Shanghai MicroPort’s Minos Stent Graft Secures Egyptian Marketing Approval

Fineline Cube May 19, 2025

China’s Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has announced that it has received...

Company Drug

Sino Biopharmaceutical’s QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain

Fineline Cube May 19, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 2.2 drug QP001 (meloxicam) has...

Company Deals

Porton Pharma Partners with Tong Eye on iPSC-Derived RPE Cell Therapies for Ophthalmic Diseases

Fineline Cube May 19, 2025

Chinese CDMO leader Porton Pharma Solutions Ltd. has entered into a strategic partnership with domestic...

Company Drug

InnoCare Pharma Doses First Patient in Phase II/III Trial of TYK2 Inhibitor for Vitiligo

Fineline Cube May 19, 2025

Chinese biotech InnoCare Pharma (HKG: 9969, SHA: 688428) has administered the first patient dose in...

Company Deals

Suzhou’s PegBio Launches Hong Kong IPO Amid Pipeline Progress

Fineline Cube May 19, 2025

Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO,...

Company

Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Market Challenges

Fineline Cube May 19, 2025

Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced last week that Lars Fruergaard...

Others

BMS Receives EC Approval for Opdivo-based Perioperative Regimen in NSCLC

Fineline Cube May 19, 2025

Bristol-Myers Squibb (BMS; NYSE: BMY) announced last week that it has received marketing authorization from...

Company Drug

Merck’s Keytruda Meets Primary Endpoint in Phase III Ovarian Cancer Trial

Fineline Cube May 19, 2025

US-based Merck Sharp & Dohme Inc. (MSD; NYSE: MRK) announced positive results from the Phase...

Company Drug

China’s AIM Vaccine Launches Clinical Trials for mRNA Shingles Vaccine in China and US

Fineline Cube May 19, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) announced the initiation of clinical trials for its...

Company Drug

FDA Approves Merck’s Welireg for Locally Advanced or Metastatic Pheochromocytoma and Paraganglioma

Fineline Cube May 16, 2025

The US Food and Drug Administration (FDA) announced this week an indication extension approval for...

Company Drug

Innovent Biologics Commences Phase III GLORY-3 Study of Mazdutide for Metabolic Dysfunction-associated Fatty Liver Disease

Fineline Cube May 16, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the Phase III...

Company Deals

Boehringer Ingelheim and Tempus Forge Multi-Year AI-Driven Oncology Drug Development Partnership

Fineline Cube May 16, 2025

Germany-based pharmaceutical major Boehringer Ingelheim has entered into a multi-year strategic collaboration with Tempus (NASDAQ:...

Company Deals

Hainan Haiyao and Elken Global Form Five-Year Strategic Partnership in Wellness Products

Fineline Cube May 16, 2025

China-based Hainan Haiyao Co., Ltd. (SHE: 000566) has entered into a five-year strategic collaboration agreement...

Company Medical Device

Beijing Balance Medical’s Renato System Gets NMPA Approval for Valve-in-Valve Therapy

Fineline Cube May 16, 2025

China’s Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has obtained market authorization from China’s...

Posts pagination

1 … 183 184 185 … 689

Recent updates

  • RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development
  • CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting
  • Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks
  • BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study – Chemotherapy-Free Regimen Shows Significant PFS Benefit
  • Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Company Drug

CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting

Company Drug

Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks

Company Drug

BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study – Chemotherapy-Free Regimen Shows Significant PFS Benefit

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.